Filtered By:
Condition: Diabetes Mellitus
Management: Food and Drug Administration (FDA)
Nutrition: Antidoxidants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M
Abstract
INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
